"Evidence Secured for Preventing Liver Metabolic Disorders and Complications"

Daewoong Pharmaceutical has confirmed the potential of its novel diabetes drug, N-blo (ingredient: inavogliflozin), to improve fatty liver in patients with type 2 diabetes.


On July 9, Daewoong Pharmaceutical announced that the results of a study confirming the potential of N-blo, an SGLT-2 inhibitor-class diabetes drug, to improve hepatic steatosis have been published in the SCI-level international journal "Diabetes, Obesity and Metabolism (DOM)." This study evaluated the impact of N-blo on "metabolic dysfunction-associated steatotic liver disease (MASLD)," a condition commonly associated with diabetes patients.


Enblo. Daewoong Pharmaceutical

Enblo. Daewoong Pharmaceutical

View original image

The research team integrated data from three clinical trials conducted for the approval of N-blo and analyzed the therapeutic effect over 24 weeks in 587 patients with type 2 diabetes. Fatty liver indices were measured using the Hepatic Steatosis Index (HSI) and Framingham Steatosis Index (FSI).


The analysis showed that a higher proportion of patients in the N-blo treatment group experienced a reduction in fatty liver indices compared to the placebo group. Among the 75 study participants, the number of patients with fatty liver based on HSI criteria decreased from 36 (48.0%) to 12 (16.0%), meaning approximately 67% of patients with pre-existing fatty liver recovered to normal levels. According to the FSI metric, the number of patients in the at-risk group decreased from 31 (41.3%) to 12 (16.0%), indicating that about 61% of at-risk patients improved to the normal range.


When compared to dapagliflozin, another drug of the same class, the N-blo treatment group achieved a greater improvement in fatty liver indices. The change in HSI for the N-blo group was -4.51, greater than the dapagliflozin group’s -3.49.



Park Hyungcheol, Head of ETC Marketing Division at Daewoong Pharmaceutical, stated, "These study results demonstrate that N-blo can provide additional therapeutic benefits beyond glycemic control by improving fatty liver indices. Given that MASLD is present in more than 65% of patients with type 2 diabetes, these findings support the potential for N-blo to expand its therapeutic value in real-world clinical settings."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing